Keros Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Keros Therapeutics's estimated annual revenue is currently $5.9M per year.
- Keros Therapeutics's estimated revenue per employee is $33,466
- Keros Therapeutics's total funding is $90M.
Employee Data
- Keros Therapeutics has 176 Employees.
- Keros Therapeutics grew their employee count by 24% last year.
Keros Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CFO | Reveal Email/Phone |
2 | Chief Medical Officer | Reveal Email/Phone |
3 | VP Clinincal Operations | Reveal Email/Phone |
4 | VP Human Resources | Reveal Email/Phone |
5 | VP Research | Reveal Email/Phone |
6 | VP, Head Regulatory Affairs | Reveal Email/Phone |
7 | VP FP&A | Reveal Email/Phone |
8 | SVP, Program and Portfolio Management | Reveal Email/Phone |
9 | Head Pharmaceutical Development and Manufacturing | Reveal Email/Phone |
10 | Head Information Technology | Reveal Email/Phone |
Keros Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Keros Therapeutics?
Keros Therapeutics is dedicated to the discovery and development of novel therapeutics for neuromuscular diseases
keywords:N/A
$90M
Total Funding
176
Number of Employees
$5.9M
Revenue (est)
24%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Keros Therapeutics News
Get Keros Therapeutics alerts: On Monday, April 4th, Jennifer Lachey sold 7,950 shares of Keros Therapeutics stock. The shares were sold...
Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients...
LEXINGTON, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorder ...
Zentalis isn’t the only biotech to defy expectations as financial markets across the globe roil from the shock of the coronavirus pandemic. Keros Therapeutics has managed to execute an IPO, hitting the top end of its pricing range and selling more shares than originally ...
Keros Therapeutics, a Lexington, MA-based company dedicated to the discovery and development of novel therapeutics for neuromuscular diseases, raised $23m in Series B financing. The round, which brings the company’s total venture funding to $34m to date, included participation from existing inv ...
Other Companies in Lexington
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $33.6M | 178 | -13% | $255.8M |
#2 | $29M | 182 | 3% | N/A |
#3 | $58.7M | 184 | 5% | N/A |
#4 | $15M | 184 | -16% | $69M |
#5 | $62.1M | 185 | 29% | N/A |